Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial

NCT06399809 Phase 2 RECRUITING

The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.

Details

Lead sponsor	Northwestern University
Phase	Phase 2
Status	RECRUITING
Enrolment	34
Start date	2024-09-30
Completion	2027-06

Conditions

• Peripheral Arterial Disease
• Aging
• Peripheral Vascular Diseases
• Walking, Difficulty
• Claudication

Interventions

• Fisetin
• Placebo

Primary outcomes

• Six-minute Walk Distance — Measured at baseline and 4 month follow-up
  Among older people with PAD, the investigators will determine whether, compared to placebo, fisetin improves six-minute walk distance at 4-month follow-up

Countries

United States